Statins considered safe for children with hereditary high cholesterol levels

Statins considered safe for children with hereditary high cholesterol levels

January 18 2018 A new study has found no statin-related safety issues for statins being used to...

Drug Safety Update includes eluxadoline, fingolimod

Drug Safety Update includes eluxadoline, fingolimod

December 19 2017 The MHRA’s latest Drug Safety Update includes information about two black...

Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

December 13 2017 Women using hormonal contraceptives are exposed to a 20% increased risk of...

MHRA issues new batch of Drug Safety Update notices

MHRA issues new batch of Drug Safety Update notices

November 28 2017 The medicines regulator has issued four Drug Safety Updates relating to...

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

Vitamin D intake guidance for pregnant mums and babies updated in Scotland

November 27 2017 NHS Scotland has updated its recommendations around vitamin D intake for new...

  • Statins considered safe for children with hereditary high cholesterol levels

    Statins considered safe for children with hereditary high cholesterol levels

    Thursday, 18 January 2018 11:07
  • Drug Safety Update includes eluxadoline, fingolimod

    Drug Safety Update includes eluxadoline, fingolimod

    Tuesday, 19 December 2017 10:16
  • Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

    Hormonal contraceptives do increase chances of breast cancer, but risk is ‘small’

    Wednesday, 13 December 2017 12:33
  • MHRA issues new batch of Drug Safety Update notices

    MHRA issues new batch of Drug Safety Update notices

    Tuesday, 28 November 2017 09:52
  • Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Vitamin D intake guidance for pregnant mums and babies updated in Scotland

    Monday, 27 November 2017 14:50

a dispensary shelves imageDecember 19 2017

The MHRA’s latest Drug Safety Update includes information about two black triangle drugs, eluxadoline and fingolimod.

The MHRA says there have been a number of reports of pancreatitis in people taking eluxadoline (Truberzi), used in treating irritable bowel syndrome with diarrhoea (IBS-D). This has led to people being admitted to hospital and has also been implicated in some deaths, primarily in people who have undergone a cholecystectomy.

The MHRA is advising that:

  • eluxadoline should only be initiated by specialists;
  • eluxadoline should not be used in patients without a gallbladder or where there is a known or suspected biliary tree or pancreatic duct obstruction;
  • patients should avoid consuming alcohol;
  • patients should be advised about symptoms which could indicate pancreatitis, so they can quickly access appropriate help.

Fingolimod (Gilenya) is indicated for use in certain patient groups with highly active relapsing remitting multiple sclerosis. Two Drug Safety Updates relating to fingolimod have been issued, the first relating to the drug having the potential to cause persistent bradycardia, increasing the risk of serious cardiac arrhythmias.

The DUS warns that fingolimod can cause serious ventricular arrhythmias, particularly in the first year of use. In addition, the drug is now contraindicated in:

  • myocardial infarction or unstable angina;
  • cerebrovascular disease;
  • certain categories of heart failure;
  • certain categories of severe cardiac arrhythmias;
  • certain types of atrioventricular (AV) block or sick‐sinus syndrome;
  • pre-treatment QT intervals ≥500 milliseconds.

The second DSU advisory for fingolimod relates to its immunosuppressant activity, its potential to increase the risk of skin cancers, lymphoma and serious opportunistic infections. Patients should be monitored closely for skin cancers, and should be advised to seek urgent attention if they develop signs or symptoms of serious infections, says the DSU. Patients should also avoid exposure to UV light, including sunlight and phototherapy.

In all cases of suspected adverse reactions to the drugs, the MHRA is asking that any suspected adverse reactions be reported via the Yellow Card scheme.

Links:
MHRA eluxadoline DSU                   
MHRA fingolimod cardio effects DSU 
MHRA fingolimod immunosuppressant activity DSU         
MHRA Drug Safety Update. December 2017. Vol. 11; issue 5                 

Clinical News

January 18 2018 A new study has found no statin-related safety issues for statins being used to treat children with familial hypercholesterolaemia. However, the research has highlighted that many...
January 18 2018 A new study has found no statin-related safety issues for statins being used to treat children with familial hypercholesterolaemia. However, the research has highlighted that many...